HomeDiscoveryPubblicazioniPubblicazioni 2017

Pubblicazioni 2017

2017

 

The target landscape of clinical kinase drugs
Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C, Zecha J, Reiter K, Qiao H, Helm D, Koch H, Schoof M, Canevari G, Casale E, Depaolini SR, Feuchtinger A, Wu Z, Schmidt T, Rueckert L, Becker W, Huenges J, Garz AK, Gohlke BO, Zolg DP, Kayser G, Vooder T, Preissner R, Hahne H, Tõnisson N, Kramer K, Götze K, Bassermann F, Schlegl J, Ehrlich HC, Aiche S, Walch A, Greif PA, Schneider S, Felder ER, Ruland J, Médard G, Jeremias I, Spiekermann K, Kuster B
Science (2017), 358(6367)
View abstract on PubMed

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1
Bosotti R, Magnaghi P, Di Bella S, Cozzi L, Cusi C, Bozzi F, Beltrami N, Carapezza G, Ballinari D, Amboldi N, Lupi R, Somaschini A, Raddrizzani L, Salom B, Galvani A, Stacchiotti S, Tamborini E, Isacchi A
Sci Rep (2017), 7(1), 9226
View abstract on PubMed

Multivalency Increases the Binding Strength of RGD Peptidomimetic-Paclitaxel Conjugates to Integrin αV β3
Raposo Moreira Dias A, Pina A, Dal Corso A, Arosio D, Belvisi L, Pignataro L, Caruso M, Gennari C.
Chemistry, (2017), 23(58), 14410-14415
View abstract on PubMed

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
Milione M, Ardini E, Christiansen J, Valtorta E, Veronese S, Bosotti R, Pellegrinelli A, Testi A, Pietrantonio F, Fucà G, Wei G, Murphy D, Siena S, Isacchi A, De Braud F
Oncotarget (2017), 8(33), 55353-55360
View abstract on PubMed

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action
Campaner E, Rustighi A, Zannini A, Cristiani A, Piazza S, Ciani Y, Kalid O, Golan G, Baloglu E, Shacham S, Valsasina B, Cucchi U, Pippione AC, Lolli ML, Giabbai B, Storici P, Carloni P, Rossetti G, Benvenuti F, Bello E, D’Incalci M, Cappuzzello E, Rosato A, Del Sal G
Nat Commun (2017), 8, 15772
View abstract on PubMed

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients
Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D’Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A
J Exp Clin Cancer Res (2017), 36(1), 63
View abstract on PubMed

Tumor Targeting with an isoDGR-Drug Conjugate
Zanella S, Angerani S, Arianna P, López Rivas P, Giannini C, Panzeri S, Arosio D, Caruso M, Gasparri F, Fraietta I, Albanese C, Marsiglio A, Pignataro L, Belvisi L, Piarulli U, Gennari C.
Chemistry (2017), 23, 7910-7914
View abstract on PubMed

The novel PIM1 inhibitor NMS-P645 reverses PIM1-dependent effects on TMPRSS2/ERG positive prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition
Mologni L, Magistroni V, Casuscelli F, Montemartini M, Gambacorti-Passerini C
J Cancer (2017), 8(1), 140-145
View abstract on PubMed

Virtual cross-linking of the active Nemorubicin metabolite PNU-159682 to double-stranded DNAs
Scalabrin M, Quintieri L, Palumbo M, Riccardi Sirtori F, Gatto B
Chem. Res. Toxico (2017), 30 (2), 614–624
View abstract on PubMed

Safety and antitumor activity of the multi-targeted Pan-TRK, ROS1, and ALK inhibitor Entrectinib (RXDX-101): combined results from two phase 1 trials (ALKA-372-001 and STARTRK-1)
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson A, Patel R1, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG
Cancer Discov (2017), (7)4, 400-409
View abstract on PubMed

miR-494-3p is a novel tumor driver of lung carcinogenesis
Faversani A, Amatori S, Augello C, Colombo F, Porretti L, Fanelli M, Ferrero S, Palleschi A, Pelicci PG, Belloni E, Ercoli G, Degrassi A, Baccarin M, Altieri DC, Vaira V, Bosari S
Oncotarget. (2017), 8(5), 7231-7247
View abstract on PubMed